Search

Your search keyword '"Melcarne L"' showing total 75 results
Start Over Author "Melcarne L"
75 results on '"Melcarne L"'

1. T.12.5: MECHANISTIC ANALYSIS OF FACTORS ASSOCIATED WITH POST COVID-19 IBS OCCURRENCE

Author

Hod, K., primary, Marasco, G., additional, Cremon, C., additional, Barbaro, M.R., additional, Colecchia, L., additional, Kagramanova, A., additional, Bordin, D., additional, Drug, V., additional, Fusaroli, P., additional, Mohamed, S.Y., additional, Ricci, C., additional, Bellini, M., additional, Rahman, M.M., additional, Melcarne, L., additional, Santos, J., additional, Bor, S., additional, Yapali, S., additional, Lukic, S., additional, Trajkovska, M., additional, Dumitrascu, D., additional, Pietrangelo, A., additional, Ghoshal, U., additional, Kolokolnikova, O., additional, Colecchia, A., additional, Serra, J., additional, Marconi, G., additional, Danese, S., additional, Portincasa, P., additional, Maggio, M., additional, Philippou, E., additional, Lee, Y.Y., additional, Stanghellini, V., additional, and Barbara, G., additional

Published
2024
Full Text
View/download PDF

2. P829 Clostridioides difficile infection in patients using vedolizumab and antiTNF: incidence and consequences (CDIFVEDO study of GETECCU)

Author

Gonzalez Vivo, M, primary, Font Ordeig, G, additional, López Romero-Salazar, F, additional, Camblor García, C, additional, Suarez Ferrer, C, additional, Melcarne, L, additional, de la Serna Gamboa, A, additional, Gómez Otero, M, additional, Hernández Camba, A, additional, Rubín de Célix, C, additional, Irabien, M, additional, Caballero-Mateos, A M, additional, García, M J, additional, Pérez Santamaria, C, additional, Vázquez García, P, additional, Castro Poceiro, J, additional, Moralejo Lozano, O, additional, Rodríguez Grau, M C, additional, Pérez Galindo, P, additional, Iglesias Doallo, A, additional, Jiménez García, N, additional, Ruiz-Rodríguez, J, additional, Teller Martin, M, additional, Riera Roig, J, additional, Marquez-Mosquera, L, additional, Benítez, J M, additional, Zabana, Y, additional, and Gutiérrez, A, additional

Published
2024
Full Text
View/download PDF

4. P895 Analysis of the efficacy of intravenous ustekinumab maintenance treatment in patients with refractory Inflammatory Bowel Disease

Author

López-Sáez, B, primary, Brunet-Mas, E, additional, Melcarne, L, additional, Puy, A, additional, Lario, S, additional, Ramirez-Lázaro, M J, additional, Llovet, L P, additional, Garcia-Sagué, B, additional, Frisancho, L E, additional, Altadill, A, additional, Villoria, A, additional, and Calvet, X, additional

Published
2024
Full Text
View/download PDF

5. OC.06.3 POST-COVID-19 IRRITABLE BOWEL SYNDROME

Author

Marasco, G., primary, Cremon, C., additional, Barbaro, M.R., additional, Falangone, F., additional, Cacciari, G., additional, Kagramanova, A., additional, Bordin, D., additional, Drug, V., additional, Fusaroli, P., additional, Mohamed, S., additional, Ricci, C., additional, Bellini, M., additional, Rahman, M., additional, Melcarne, L., additional, Santos, J., additional, Bor, S., additional, Yapali, S., additional, Lukic, S., additional, Trajkovska, M., additional, Hod, K., additional, Dumitrascu, D., additional, Pietrangelo, A., additional, Simren, M., additional, Ghoshal, U., additional, Kolokolnikova, O., additional, Colecchia, A., additional, Serra, J., additional, Maconi, G., additional, De Giorgio, R., additional, Danese, S., additional, Portincasa, P., additional, Di Sabatino, A., additional, Maggio, M., additional, Philippou, E., additional, Stanghellini, V., additional, and Barbara, G., additional

Published
2023
Full Text
View/download PDF

6. OP26 Impact of telemonitoring on the management of Inflammatory Bowel Disease in Spain: a multicenter TECCU clinical trial

Author

Aguas Peris, M, primary, Del Hoyo, J, additional, Vicente, R, additional, Barreiro-de Acosta, M, additional, Melcarne, L, additional, Hernández-Camba, A, additional, Alfambra, E, additional, Madero, L, additional, Sicilia, B, additional, Chaparro, M, additional, Martín-Arranz, M D, additional, Pajares, R, additional, Mesonero, F, additional, Mañosa, M, additional, Martínez, P, additional, Chacón, S, additional, Tosca, J, additional, Marín, S, additional, Sanromán, L, additional, Calvo, M, additional, Monfort, D, additional, Saiz, E, additional, Zabana, Y, additional, Guerra, I, additional, Varela, P, additional, Faubel, R, additional, Corsino, P, additional, Porto-Silva, S, additional, Brunet, E, additional, Gutiérrez, A, additional, and Nos, P, additional

Published
2023
Full Text
View/download PDF

9. USEFULNESS OF THE MODIFIED ROCKALL INDEX TO PREDICT ADVERSE EVENTS IN UPPER GASTROINTESTINAL BLEEDING DUE TO PEPTIC ULCER

Author

Pedregal, P., additional, Llovet, L., additional, Brunet, E., additional, Garcia-Iglesias, P., additional, Lira, A., additional, Machlab, S., additional, Grau, G., additional, Junquera, F., additional, Melcarne, L., additional, Puig-Diví, V., additional, Calvet, X., additional, Brullet, E., additional, and Martínez-Bauer, E., additional

Published
2022
Full Text
View/download PDF

10. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

Author

Zabana Y, Marín-Jiménez I, Rodríguez-Lago I, Vera I, Martín-Arranz MD, Guerra I, Gisbert JP, Mesonero F, Benítez O, Taxonera C, Ponferrada-Díaz Á, Piqueras M, Lucendo AJ, Caballol B, Mañosa M, Martínez-Montiel P, Bosca-Watts M, Gordillo J, Bujanda L, Manceñido N, Martínez-Pérez T, López A, Rodríguez-Gutiérrez C, García-López S, Vega P, Rivero M, Melcarne L, Calvo M, Iborra M, Barreiro de-Acosta M, Sicilia B, Barrio J, Pérez JL, Busquets D, Pérez-Martínez I, Navarro-Llavat M, Hernández V, Argüelles-Arias F, Ramírez Esteso F, Meijide S, Ramos L, Gomollón F, Muñoz F, Suris G, de Zarate JO, Huguet JM, Llaó J, García-Sepulcre MF, Sierra M, Durà M, Estrecha S, Fuentes Coronel A, Hinojosa E, Olivan L, Iglesias E, Gutiérrez A, Varela P, Rull N, Gilabert P, Hernández-Camba A, Brotons A, Ginard D, Sesé E, Carpio D, Aceituno M, Cabriada JL, González-Lama Y, Jiménez L, Chaparro M, López-San Román A, Alba C, Plaza-Santos R, Mena R, Tamarit-Sebastián S, Ricart E, Calafat M, Olivares S, Navarro P, Bertoletti F, Alonso-Galán H, Pajares R, Olcina P, Manzano P, Domènech E, Esteve M, On Behalf Of The Eneida Registry Of Geteccu, [Zabana Y] Hospital Universitari Mútua Terrassa, Terrassa, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain. [Marín-Jiménez I] Hospital Gregorio Marañón, Madrid, Spain. [Rodríguez-Lago I] Gastroenterology Department, Hospital Universitario de Galdakao, Galdakao, Spain. Biocruces Bizkaia Health Research Institute, Galdakao, Spain. [Vera I] Hospital Universitario Puerta de Hierro, Majadahonda, Spain. [Martín-Arranz MD] Hospital Universitario La Paz, Madrid, Spain. [Guerra I] Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain. Instituto de Investigación Hospital Universitario La Paz (IdiPaz), Madrid, Spain. [Piqueras M, Mena R] Servei de Digestologia, Hospital de Terrassa, Consorci Sanitari de Terrassa, Terrassa, Spain, Consorci Sanitari de Terrassa, and Universidad de Sevilla. Departamento de Medicina

Subjects
index, Pronòstic mèdic, Risk factors in diseases, COVID-19 (Malaltia), Article, Inflammatory bowel disease, Comorbiditat, inflammatory bowel disease, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Epidemiology and Biostatistics::Epidemiology::Health-Disease Process::Comorbidity [PUBLIC HEALTH], Factors de risc en les malalties, SARS-CoV-2, COVID-19, determinants, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], General Medicine, Prognosis, enfermedades del sistema digestivo::enfermedades gastrointestinales::enfermedades del sistema digestivo::enfermedades gastrointestinales::enfermedades intestinales::enfermedad inflamatoria intestinal [ENFERMEDADES], infection, epidemiología y bioestadística::epidemiología::proceso salud-enfermedad::comorbilidad [SALUD PÚBLICA], Medicine, Digestive System Diseases::Gastrointestinal Diseases::Digestive System Diseases::Gastrointestinal Diseases::Intestinal Diseases::Inflammatory Bowel Diseases [DISEASES], Intestins - Inflamació
Abstract

We aim to describe the incidence and source of contagion of COVID-19 in patients with IBD, as well as the risk factors for a severe course and long-term sequelae. This is a prospective observational study of IBD and COVID-19 included in the ENEIDA registry (53,682 from 73 centres) between March-July 2020 followed-up for 12 months. Results were compared with data of the general population (National Centre of Epidemiology and Catalonia). A total of 482 patients with COVID-19 were identified. Twenty-eight percent were infected in the work environment, and 48% were infected by intrafamilial transmission, despite having good adherence to lockdown. Thirty-five percent required hospitalization, 7.9% had severe COVID-19 and 3.7% died. Similar data were reported in the general population (hospitalisation 19.5%, ICU 2.1% and mortality 4.6%). Factors related to death and severe COVID-19 were being aged >= 60 years (OR 7.1, 95% CI: 1.8-27 and 4.5, 95% CI: 1.3-15.9), while having >= 2 comorbidities increased mortality (OR 3.9, 95% CI: 1.3-11.6). None of the drugs for IBD were related to severe COVID-19. Immunosuppression was definitively stopped in 1% of patients at 12 months. The prognosis of COVID-19 in IBD, even in immunosuppressed patients, is similar to that in the general population. Thus, there is no need for more strict protection measures in IBD. This study is funded by the Carlos III Health Institute (COV20/00227: Co-IP Dra. Maria Esteve and Dra. Yamile Zabana), FEDER (Fondo Europeo de Desarrollo Regional) and supported by GETECCU. The ENEIDA Registry of GETECCU is supported by Takeda, Pfizer, Galapagos, AbbVie and Biogen.

Published
2022

11. Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study

Author

Marasco, G., Cremon, C., Barbaro, M. R., Salvi, D., Cacciari, G., Kagramanova, A., Bordin, D., Drug, V., Miftode, E., Fusaroli, P., Mohamed, S. Y., Ricci, C., Bellini, M., Rahman, M. M., Melcarne, L., Santos, J., Lobo, B., Bor, S., Yapali, S., Akyol, D., Sapmaz, F. P., Urun, Y. Y., Eskazan, T., Celebi, A., Kacmaz, H., Ebik, B., Binicier, H. C., Bugdayci, M. S., Yagci, M. B., Pullukcu, H., Kaya, B. Y., Tureyen, A., Hatemi, I., Koc, E. S., Sirin, G., Caliskan, A. R., Bengi, G., Alis, E. E., Lukic, S., Trajkovska, M., Hod, K., Dumitrascu, D., Pietrangelo, A., Corradini, E., Simren, M., Sjolund, J., Tornkvist, N., Ghoshal, U. C., Kolokolnikova, O., Colecchia, A., Serra, J., Maconi, G., De Giorgio, R., Danese, S., Portincasa, P., Di Stefano, M., Maggio, M., Philippou, E., Lee, Y. Y., Venturi, A., Borghi, C., Zoli, M., Gionchetti, P., Viale, P., Stanghellini, V., Barbara, G., Piacentini, A., Shengelia, M., Vechorko, V., Cardamone, C., Rosei, C. A., Pancetti, A., Rettura, F., Pedrosa, M., Campoli, C., Mijac, D., Korac, M., Karic, U., Markovic, A., Najdeski, A., Nikolova, D., Dimzova, M., Lior, O., Shinhar, N., Perelmutter, O., Ringel, Y., Sabo, C. M., Chis, A., Bonucchi, G., Caio, G. P. I., Ghirardi, C., Marziani, B., Rizzello, B., Aguilar, A., Capogreco, A., Aghemo, A., Di Paolo, D. M., Marconi, G., Di Sabatino, A., Tagliaferri, S., Naves, J. E., Galli, A., Dragoni, G., Nedelcu, L., Mauloni, P. A., Del Vecchio, S., Rotondo, L., Capuani, F., Montanari, D., Palombo, F., Paone, C., Mastel, G., Fontana, C., Bellacosa, L., Cogliandro, R. F., Marasco, Giovanni, Cremon, Cesare, Barbaro, Maria Raffaella, Salvi, Daniele, Cacciari, Giulia, Kagramanova, Anna, Bordin, Dmitry, Drug, Vasile, Miftode, Edgidia, Fusaroli, Pietro, Mohamed, Salem Youssef, Ricci, Chiara, Bellini, Massimo, Rahman, M Masudur, Melcarne, Luigi, Santos, Javier, Lobo, Beatriz, Bor, Serhat, Yapali, Suna, Akyol, Deniz, Sapmaz, Ferdane Pirincci, Urun, Yonca Yilmaz, Eskazan, Tugce, Celebi, Altay, Kacmaz, Huseyin, Ebik, Berat, Binicier, Hatice Cilem, Bugdayci, Mehmet Sait, Yağcı, Munkhtsetseg Banzragch, Pullukcu, Husnu, Kaya, Berrin Yalınba, Tureyen, Ali, Hatemi, İbrahim, Koc, Elif Sitre, Sirin, Goktug, Calıskan, Ali Riza, Bengi, Goksel, Alıs, Esra Ergun, Lukic, Snezana, Trajkovska, Meri, Hod, Keren, Dumitrascu, Dan, Pietrangelo, Antonello, Corradini, Elena, Simren, Magnu, Sjolund, Jessica, Tornkvist, Navkiran, Ghoshal, Uday C, Kolokolnikova, Olga, Colecchia, Antonio, Serra, Jordi, Maconi, Giovanni, De Giorgio, Roberto, Danese, Silvio, Portincasa, Pietro, Di Stefano, Michele, Maggio, Marcello, Philippou, Elena, Lee, Yeong Yeh, Venturi, Alessandro, Borghi, Claudio, Zoli, Marco, Gionchetti, Paolo, Viale, Pierluigi, Stanghellini, Vincenzo, and Barbara, Giovanni

Subjects
Male, medicine.medical_specialty, Settore MED/17 - Malattie Infettive, Coronavirus disease 2019 (COVID-19), Nausea, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), diarrhea, Disease, Gastrointestinal Symptoms, COVID-19, Acute Respiratory Syndrome, GI-COVID-19, NO, Russia, Manifestations, Interviews as Topic, Rating scale, Internal medicine, Surveys and Questionnaires, parasitic diseases, medicine, Prevalence, Humans, In patient, Prospective Studies, Respiratory system, Settore MED/12 - Gastroenterologia, Hepatology, business.industry, SARS-CoV-2, pandemic, Gastroenterology, COVID-19, Middle Aged, gastrointestinal, Gastroenteritis, Europe, Hospital admission, Egypt, Female, medicine.symptom, business, human activities
Abstract

INTRODUCTION: Gastrointestinal (GI) symptoms in coronavirus-19 disease (COVID-19) have been reported with great variability and without standardization. In hospitalized patients, we aimed to evaluate the prevalence of GI symptoms, factors associated with their occurrence, and variation at 1 month. METHODS: The GI-COVID-19 is a prospective, multicenter, controlled study. Patients with and without COVID-19 diagnosis were recruited at hospital admission and asked for GI symptoms at admission and after 1 month, using the validated Gastrointestinal Symptom Rating Scale questionnaire. RESULTS: The study included 2036 hospitalized patients. A total of 871 patients (575 COVID+ and 296 COVID-) were included for the primary analysis. GI symptoms occurred more frequently in patients with COVID-19 (59.7%; 343/575 patients) than in the control group (43.2%; 128/296 patients) (P < 0.001). Patients with COVID-19 complained of higher presence or intensity of nausea, diarrhea, loose stools, and urgency as compared with controls. At a 1-month follow-up, a reduction in the presence or intensity of GI symptoms was found in COVID-19 patients with GI symptoms at hospital admission. Nausea remained increased over controls. Factors significantly associated with nausea persistence in COVID-19 were female sex, high body mass index, the presence of dyspnea, and increased C-reactive protein levels. DISCUSSION: The prevalence of GI symptoms in hospitalized patients with COVID-19 is higher than previously reported. Systemic and respiratory symptoms are often associated with GI complaints. Nausea may persist after the resolution of COVID-19 infection., Fondazione Cassa di Risparmio in Bologna; Italian Ministry of Education, University and Research; Fondazione del Monte di Bologna e Ravenna [SC1-BHC-01-2019]; European Grant H2020, DISCOvERIE [SC1-BHC-01-2019]; Italian Ministry of Health [Ricerca Finalizzata GR-2018-12367062], G.B. contribution to this research was permitted in part by funding from Fondazione Cassa di Risparmio in Bologna; the ItalianMinistry of Education, University and Research; and Fondazione del Monte di Bologna e Ravenna and European Grant H2020, DISCOvERIE, SC1-BHC-01-2019. M.R.B. is a recipient of a grant from the Italian Ministry of Health (Ricerca Finalizzata GR-2018-12367062). None of the funding organizations have had any role in the design and conduct of the study; in the collection, management, and analysis of the data; or in the preparation, review, and approval of the article.

Published
2022

12. Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy

Author

Bermejo F, Jiménez L, Algaba A, Vela M, Bastida G, Merino O, López-García A, Melcarne L, Rodríguez-Lago I, de la Maza S, Bouhmidi A, Barreiro-de Acosta M, López-Serrano P, Carrillo-Palau M, Mesonero F, Orts B, Bonillo D, Granja A, and Guerra I

Subjects
Crohn’s disease, loss of response, re-induction, ustekinumab
Abstract

BACKGROUND: A significant percentage of patients treated with ustekinumab may lose response. Our aim was to evaluate the short-term efficacy and safety of intravenous re-induction with ustekinumab in patients with Crohn's disease who have lost the response to the treatment. METHODS: This is a retrospective, observational, multicenter study. Treatment efficacy was measured at week 8 and 16; clinical remission was defined when the Harvey-Bradshaw Index was =4 points, and clinical response was defined as a decrease of =3 points in the index compared with the baseline. Adverse events and treatment decisions after re-induction were also collected. RESULTS: Fifty-three patients from 13 centers were included. Forty-nine percent had previously failed to respond to 2 biological treatments, and 24.5% had failed to respond to 3. The average exposure time to ustekinumab before re-induction was 17.7 ± 12.8 months. In 56.6% of patients, the administration interval had been shortened to every 4 to 6 weeks before re-induction. At week 8 and 16 after re-induction, 49.0% (n = 26) and 43.3% (n = 23), respectively, were in remission, whereas 64.1% (n = 34) and 52.8% (n = 28) had a clinical response. Patients who achieved remission at week 16 had lower C-reactive protein levels than those who did not respond (2.8 ± 1.6 vs 12.5 ± 9.5 mg/dL; P = 0.001). No serious adverse events related to re-induction were observed. CONCLUSION: Intravenous re-induction with ustekinumab is an effective and safe strategy that recovers the response in approximately half of the patients with refractory Crohn's disease who experience a loss of response. Re-induction can be attempted before switching out of the therapy class.

Published
2022

13. P523 Effectiveness of biological treatments for inflammatory bowel disease in the elderly patients

Author

Suarez Ferrer, C J, primary, Mesonero, F, additional, Caballol, B, additional, Ballester, M P, additional, Baston Rey, I, additional, Castaño Garcia, A, additional, Miranda Bautista, J, additional, Saiz Chumillas, R, additional, Benitez, J M, additional, Sanchez Delgado, L, additional, Lopez-Garcia, A, additional, Rubin de Celix, C, additional, Martin-Arranz, M D, additional, Lopez Sanroman, A, additional, Fernandez-Clotet, A, additional, Merino Murgui, V, additional, Calviño Suarez, C, additional, Florez, P, additional, Lobato Matilla, M E, additional, Sicilia, B, additional, Soto Escribano, P, additional, Maroto Martin, C, additional, Alonso Abreu, I, additional, Melcarne, L, additional, Elena, P G, additional, Iyo, E, additional, Elosua Gonzalez, A, additional, Saiz, E, additional, Hernandez Villalba, L, additional, Perez Galindo, P, additional, Torrealba Medina, L, additional, Monsalve Alonso, S, additional, Olmos Jerez, J A, additional, Dueñas Sadornil, C, additional, and Barreiro-De Acosta, M, additional

Published
2022
Full Text
View/download PDF

14. P410 Safety of biological drugs for inflammatory bowel disease in elderly patients

Author

Suarez Ferrer, C J, primary, Mesonero, F, additional, Caballol, B, additional, Ballester, M P, additional, Baston Rey, I, additional, Castaño Garcia, A, additional, Miranda Bautista, J, additional, Saiz Chumillas, R, additional, Benitez, J M, additional, Sanchez Delgado, L, additional, Lopez-Garcia, A, additional, Rubin de Celix, C, additional, Lopez Sanroma, A, additional, Martin-Arranz, M D, additional, Fernández-Clotet, A, additional, Merino Murgui, V, additional, Calviño Suárez, C, additional, Florez, P, additional, Lobato matilla, M E, additional, Sicilia, B, additional, Soto Escribano, P, additional, Maroto Martin, C, additional, Alonso Abreu, I, additional, Melcarne, L, additional, Plaza Santos, R, additional, Marques Cami, M, additional, Caballero Mateos, A, additional, Gómez Díez, C, additional, Calafat, M, additional, Alonso Galan, H, additional, Vega Villaamil, P, additional, Castro Senosiain, B, additional, Guerro Moya, A, additional, Rodriguez Diaz, C Y, additional, Spicakova, K, additional, Manceñido Marcos, N, additional, Molina, G, additional, De Castro, L, additional, Mañosa Ciria, M, additional, and Barreiro-De Acosta, M, additional

Published
2022
Full Text
View/download PDF

15. P481 Profile of elderly patients in which biological drugs are used for the treatment of inflammatory bowel disease

Author

Suarez Ferrer, C J, primary, Mesonero, F, additional, Caballol, B, additional, Ballester, M P, additional, Baston Rey, I, additional, Castaño Garcia, A, additional, Miranda Bautista, J, additional, Saiz Chumillas, R, additional, Benitez, J M, additional, Sanchez Delgado, L, additional, Lopez-Garcia, A, additional, Rubin de Celio, C, additional, Alonso Abreu, I, additional, Melcarne, L, additional, Plaza Santos, R, additional, Marques Cami, M, additional, Caballero Mateos, A, additional, Gomez Diez, C, additional, Calafat, M, additional, Alonso Galan, H, additional, Vega Vilaamil, P, additional, Castro Sensosian, B, additional, Guerro Moya, A, additional, Rodriguez Diaz, C Y, additional, Spicakova, K, additional, Manceñido Marcos, N, additional, Molina, G, additional, De Castro, L, additional, Rodriguez Angulo, A, additional, Cuevas del Campo, L, additional, Rodriguez Grau, M C, additional, Ramirez, F, additional, Gomez Pastrana, B, additional, Gonzalez Partida, I, additional, Botella Mateu, B, additional, Peña Gonzalez, E, additional, Iyo, E, additional, Elosua Gonzalez, A, additional, Mañosa Ciria, M, additional, and Barreiro-De Acosta, M, additional

Published
2022
Full Text
View/download PDF

16. Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease: A Multicentre Study of Geteccu

Author

García, M. J., Rivero, M., Miranda-Bautista, J., Bastón-Rey, I., Mesonero, F., Leo-Carnerero, E., Casas-Deza, D., Cagigas Fernández, C., Martin-Cardona, A., El Hajra, I., Hernández-Aretxabaleta, N., Pérez-Martínez, I., Fuentes-Valenzuela, E., Jiménez, N., Rubin de Célix, C., Gutiérrez, A., Suárez Ferrer, C., Huguet, J. M., Fernández-Clotet, A., González-Vivó, M., Del Val, B., Castro-Poceiro, J., Melcarne, L., Dueñas, C., Izquierdo, M., Monfort, D., Bouhmidi, A., Ramírez de la Piscina, P., Romero, E., Molina, G., Zorrilla, J., Calvino-Suárez, C., Sánchez, E., Núñez, A., Sierra, O., Castro, B., Zabana, Y., González-Partida, I., De la Maza, S., Castaño, A., Nájera-Muñoz, R., Sánchez-Guillén, L., Riat Castro, M., Rueda, J. L., Benítez, J. M., Delgado-Guillena, P., Tardillo, C., Peña, E., Frago-Larramona, S., Rodríguez-Grau. M. C., Plaza, R., Pérez-Galindo, P., Martínez-Cadilla, J., Menchén, L., Barreiro-De Acosta, M., Sánchez-Aldehuelo, R., De la Cruz, M. D., Lamuela, L. J., Marín, I., Nieto-García, L., López San Román, A., Herrera, J. M., Chaparro, M., Gisbert, J. P., Young Group of GETECCU, [García MJ, Rivero M] Gastroenterology Department, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Instituto de Investigación Sanitaria Valdecilla (IDIVAL), Santander, Spain. [Miranda-Bautista J] Gastroenterology Department, Hospital Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), and Departamento de Medicina, Universidad Complutense, Madrid, Spain. [Bastón-Rey I] Gastroenterology Department, Hospital Universitario Clínico de Santiago, Santiago de Compostela, Spain. [Mesonero F] Gastroenterology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain. [Leo-Carnerero E] Gastroenterology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain. [Delgado-Guillena P] Gastroenterology Department, Hospital General de Granollers, Granollers, Spain, Hospital General de Granollers, [Jose Garcia, Maria] Univ Cantabria, Hosp Univ Marques de Valdecilla, Inst Invest Sanitaria Valdecilla IDIVAL, Gastroenterol Dept, Santander 37008, Spain, [Rivero, Montserrat] Univ Cantabria, Hosp Univ Marques de Valdecilla, Inst Invest Sanitaria Valdecilla IDIVAL, Gastroenterol Dept, Santander 37008, Spain, [Castro, Beatriz] Univ Cantabria, Hosp Univ Marques de Valdecilla, Inst Invest Sanitaria Valdecilla IDIVAL, Gastroenterol Dept, Santander 37008, Spain, [Miranda-Bautista, Jose] Univ Complutense, Hosp Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon IiSGM, Gastroenterol Dept, Madrid 28009, Spain, [Menchen, Luis] Univ Complutense, Hosp Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon IiSGM, Gastroenterol Dept, Madrid 28009, Spain, [Marin, Ignacio] Univ Complutense, Hosp Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon IiSGM, Gastroenterol Dept, Madrid 28009, Spain, [Miranda-Bautista, Jose] Univ Complutense, Dept Med, Madrid 28009, Spain, [Menchen, Luis] Univ Complutense, Dept Med, Madrid 28009, Spain, [Marin, Ignacio] Univ Complutense, Dept Med, Madrid 28009, Spain, [Baston-Rey, Iria] Hosp Univ Clin Santiago, Gastroenterol Dept, Santiago De Compostela 15706, Spain, [Calvino-Suarez, Cristina] Hosp Univ Clin Santiago, Gastroenterol Dept, Santiago De Compostela 15706, Spain, [Barreiro-De Acosta, Manuel] Hosp Univ Clin Santiago, Gastroenterol Dept, Santiago De Compostela 15706, Spain, [Nieto-Garcia, Laura] Hosp Univ Clin Santiago, Gastroenterol Dept, Santiago De Compostela 15706, Spain, [Mesonero, Francisco] Hosp Univ Ramon y Cajal, Gastroenterol Dept, Madrid 28034, Spain, [Sanchez, Eugenia] Hosp Univ Ramon y Cajal, Gastroenterol Dept, Madrid 28034, Spain, [Sanchez-Aldehuelo, Ruben] Hosp Univ Ramon y Cajal, Gastroenterol Dept, Madrid 28034, Spain, [Lopez-San Roman, Antonio] Hosp Univ Ramon y Cajal, Gastroenterol Dept, Madrid 28034, Spain, [Leo-Carnerero, Eduardo] Hosp Univ Virgen del Rocio, Gastroenterol Dept, Seville 41013, Spain, [Nunez, Andrea] Hosp Univ Virgen del Rocio, Gastroenterol Dept, Seville 41013, Spain, [Dolores De la Cruz, Maria] Hosp Univ Virgen del Rocio, Gastroenterol Dept, Seville 41013, Spain, [Manuel Herrera, Jose] Hosp Univ Virgen del Rocio, Gastroenterol Dept, Seville 41013, Spain, [Casas-Deza, Diego] Hosp Univ Miguel Servet, Inst Invest Sanitaria Aragon IISA, Gastroenterol Dept, Zaragoza 50009, Spain, [Sierra, Olivia] Hosp Univ Miguel Servet, Inst Invest Sanitaria Aragon IISA, Gastroenterol Dept, Zaragoza 50009, Spain, [Javier Lamuela, Luis] Hosp Univ Miguel Servet, Inst Invest Sanitaria Aragon IISA, Gastroenterol Dept, Zaragoza 50009, Spain, [Cagigas Fernandez, Carmen] Hosp Univ Marques de Valdecilla, Dept Gen & Digest Surg, Colorectal Unit, Santander 39008, Spain, [Martin-Cardona, Albert] Hosp Univ Mutua Terrassa, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Gastroenterol Dept, Terrassa 08221, Spain, [Zabana, Yamile] Hosp Univ Mutua Terrassa, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Gastroenterol Dept, Terrassa 08221, Spain, [El Hajra, Ismael] Hosp Univ Puerta de Hierro, Gastroenterol Dept, Majadahonda 28220, Spain, [Gonzalez-Partida, Irene] Hosp Univ Puerta de Hierro, Gastroenterol Dept, Majadahonda 28220, Spain, [Hernandez-Aretxabaleta, Nerea] Hosp Univ Basurto, Gastroenterol Dept, Bilbao 48013, Spain, [De la Maza, Saioa] Hosp Univ Basurto, Gastroenterol Dept, Bilbao 48013, Spain, [Perez-Martinez, Isabel] Hosp Univ Cent Asturias, Inst Invest Sanitaria Principado Asturias ISPA 33, Dept Gastroenterol, Oviedo 33011, Spain, [Castano, Andres] Hosp Univ Cent Asturias, Inst Invest Sanitaria Principado Asturias ISPA 33, Dept Gastroenterol, Oviedo 33011, Spain, [Fuentes-Valenzuela, Esteban] Hosp Univ Rio Hortega, Gastroenterol Dept, Valladolid 47012, Spain, [Najera-Munoz, Rodrigo] Hosp Univ Rio Hortega, Gastroenterol Dept, Valladolid 47012, Spain, [Jimenez, Nuria] Hosp Gen Univ Elche, Gastroenterol Dept, Alicante 03203, Spain, [Rubin de Celix, Cristina] Univ Autonoma Madrid UAM, Gastroenterol Dept, Hosp Univ La Princesa, Inst Invest Sanitaria Princesa IIS IP,Ctr Invest, Madrid 28006, Spain, [Castro, Micaela Riat] Univ Autonoma Madrid UAM, Gastroenterol Dept, Hosp Univ La Princesa, Inst Invest Sanitaria Princesa IIS IP,Ctr Invest, Madrid 28006, Spain, [Chaparro, Maria] Univ Autonoma Madrid UAM, Gastroenterol Dept, Hosp Univ La Princesa, Inst Invest Sanitaria Princesa IIS IP,Ctr Invest, Madrid 28006, Spain, [Gisbert, Javier P.] Univ Autonoma Madrid UAM, Gastroenterol Dept, Hosp Univ La Princesa, Inst Invest Sanitaria Princesa IIS IP,Ctr Invest, Madrid 28006, Spain, [Gutierrez, Ana] Hosp Gen Alicante, Gastroenterol Dept, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inst Invest Sanitaria & Biomed Alicante ISABIAL, Alicante 03010, Spain, [Suarez Ferrer, Cristina] Hosp Univ La Paz, Gastroenterol Dept, Madrid 28046, Spain, [Luis Rueda, Jose] Hosp Univ La Paz, Gastroenterol Dept, Madrid 28046, Spain, [Maria Huguet, Jose] Hosp Gen Univ Valencia, Gastroenterol Dept, Valencia 46014, Spain, [Fernandez-Clotet, Agnes] Hosp Clin Barcelona, Gastroenterol Dept, Barcelona 08036, Spain, [Gonzalez-Vivo, Maria] Hosp del Mar, Gastroenterol Dept, Barcelona 08003, Spain, [Del Val, Blanca] Hosp Rafael Mendez, Gastroenterol Dept, Lorca 30817, Spain, [Castro-Poceiro, Jesus] Hosp St Joan Despi Moises Broggi, Gastroenterol Dept, Barcelona 08970, Spain, [Melcarne, Luigi] Hosp Univ Parc Tauli, Gastroenterol Dept, Sabadell, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona 08208, Spain, [Duenas, Carmen] Hosp Univ Caceres, Gastroenterol Dept, Caceres 10003, Spain, [Izquierdo, Marta] Hosp Univ Cabuenes, Gastroenterol Dept, Gijon 33203, Spain, [Monfort, David] Consorcio Sanitario Terrasa, Gastroenterol Dept, Barcelona 08227, Spain, [Bouhmidi, Abdel] Hosp Santa Barbara, Gastroenterol Dept, Puertollano 13500, Spain, [Ramirez De la Piscina, Patricia] Hosp Univ Vitoria Gasteiz, Gastroenterol Dept, Vitoria 01002, Spain, [Romero, Eva] Hosp Clin Univ Valencia, Gastroenterol Dept, Valencia 46010, Spain, [Molina, Gema] Hosp Arquitecto Marcide, Gastroenterol Dept, Ferrol 15405, Spain, [Zorrilla, Jaime] Hosp Univ Gregorio Maranon, Dept Colorectal & Gastrointestinal Surg, Madrid 28009, Spain, [Sanchez-Guillen, Luis] Hosp Gen Univ Elche, Dept Colorectal & Gastrointestinal Surg, Alicante 03203, Spain, [Manuel Benitez, Jose] Hosp Reina Sofia, Gastroenterol Dept, IMIBIC, Cordoba 14004, Spain, [Delgado-Guillena, Pedro] Hosp Gen Granollers, Gastroenterol Dept, Granollers 08042, Spain, [Tardillo, Carlos] Hosp Nuestra Sanora de la Candelaria, Gastroenterol Dept, Tenerife 38010, Spain, [Pena, Elena] Hosp Royo Villanova, Gastroenterol Dept, Zaragoza 50007, Spain, [Frago-Larramona, Santiago] Complejo Hosp Soria, Gastroenterol Dept, Soria 42005, Spain, [Carmen Rodriguez-Grau, Maria] Hosp Univ Henares, Gastroenterol Dept, Coslada 28002, Spain, [Plaza, Rocio] Hosp Univ Infanta Leonor, Gastroenterol Dept, Madrid 28031, Spain, [Perez-Galindo, Pablo] Complejo Hosp Univ Pontevedra, Gastroenterol Dept, Pontevedra 36071, Spain, [Martinez-Cadilla, Jesus] Hosp Alvaro Cunqueiro Vigo, Gastroenterol Dept, Vigo 36312, Spain, and Spanish Working Group in Crohn's Disease and Ulcerative Colitis (GETECCU)

Subjects
Gastroenterología y hepatología, Crohn’s disease, vedolizumab, medicine.medical_specialty, Crohns-disease, Cirurgia - Complicacions, Surgical complications, Productes biològics, Digestive System Diseases::Gastrointestinal Diseases::Gastroenteritis::Inflammatory Bowel Diseases::Crohn Disease [DISEASES], Outcomes, Pathological Conditions, Signs and Symptoms::Pathologic Processes::Postoperative Complications [DISEASES], Crohn, Malaltia de, Lower risk, Inflammatory bowel disease, Article, ustekinumab, Vedolizumab, surgery, inflammatory bowel disease, Internal medicine, Ustekinumab, postoperative complications, Medicine, Risk factor, ulcerative colitis, Crohn's disease, preoperative therapy, business.industry, Postoperative infectious complications, Retrospective cohort study, General Medicine, anti-TNF, Metaanalysis, medicine.disease, Resection, mezclas complejas::productos biológicos [COMPUESTOS QUÍMICOS Y DROGAS], Ulcerative colitis, afecciones patológicas, signos y síntomas::procesos patológicos::complicaciones posoperatorias [ENFERMEDADES], Gastrointestinal surgery, enfermedades del sistema digestivo::enfermedades gastrointestinales::gastroenteritis::enfermedad inflamatoria intestinal::enfermedad de Crohn [ENFERMEDADES], Risk-factors, Ulcerative-colitis, Preoperative steroid use, Complex Mixtures::Biological Products [CHEMICALS AND DRUGS], business, medicine.drug
Abstract

Background: The impact of biologics on the risk of postoperative complications (PC) in inflammatory bowel disease (IBD) is still an ongoing debate. This lack of evidence is more relevant for ustekinumab and vedolizumab. Aims: To evaluate the impact of biologics on the risk of PC. Methods: A retrospective study was performed in 37 centres. Patients treated with biologics within 12 weeks before surgery were considered “exposed”. The impact of the exposure on the risk of 30-day PC and the risk of infections was assessed by logistic regression and propensity score-matched analysis. Results: A total of 1535 surgeries were performed on 1370 patients. Of them, 711 surgeries were conducted in the exposed cohort (584 anti-TNF, 58 vedolizumab and 69 ustekinumab). In the multivariate analysis, male gender (OR: 1.5, 95% CI: 1.2–2.0), urgent surgery (OR: 1.6, 95% CI: 1.2–2.2), laparotomy approach (OR: 1.5, 95% CI: 1.1–1.9) and severe anaemia (OR: 1.8, 95% CI: 1.3–2.6) had higher risk of PC, while academic hospitals had significantly lower risk. Exposure to biologics (either anti-TNF, vedolizumab or ustekinumab) did not increase the risk of PC (OR: 1.2, 95% CI: 0.97–1.58), although it could be a risk factor for postoperative infections (OR 1.5, 95% CI: 1.03–2.27). Conclusions: Preoperative administration of biologics does not seem to be a risk factor for overall PC, although it may be so for postoperative infections.

Published
2021

18. Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy

Author

Bermejo F, Jiménez L, Algaba A, Vela M, Bastida G, Merino O, López-García A, Melcarne L, Rodríguez-Lago I, de la Maza S, Bouhmidi A, Barreiro-de Acosta M, López-Serrano P, Carrillo-Palau M, Mesonero F, Bonillo D, Granja A, and Guerra I

Subjects
Crohn’s disease, loss of response, re-induction, ustekinumab
Abstract

A significant percentage of patients treated with ustekinumab may lose response. Our aim was to evaluate the short-term efficacy and safety of intravenous re-induction with ustekinumab in patients with Crohn's disease who have lost the response to the treatment.

Published
2021

19. Comorbidities and epidemiological risk factor but not immunosuppressive therapies increase the risk of COVID-19 in Inflammatory Bowel Disease (IBD): An ENEIDA-based, case-control study

Author

Abdo, YZ, Marin-Jimenez, I, Rodriguez-Lago, I, Vera, I, Martin, MD, Guerra, I, Gisbert, JP, Mesonero, F, Benitez, O, Taxonera, C, Ponferrada-Diaz, A, Piqueras, M, Lucendo, A, Caballol, B, Manosa, M, Martinez-Montiel, P, Bosca-Watts, M, Gordillo, J, Bujanda, L, Mancenido, N, Martinez-Perez, T, Lopez, A, Rodriguez, C, Garcia-Lopez, S, Vega, P, Rivero, M, Melcarne, L, Calvo, M, Iborra, M, Barreiro-de Acosta, M, Arias, L, Barrio, J, Perez, JL, Busquets, D, Perez-Martinez, I, Navarro-Llavat, M, Hernandez, V, Arguelles-Arias, F, Domenech, E, and Esteve, M

Published
2021

20. Impact of biological agents on postoperative complications in inflammatory bowel disease: a multicentre study of GETECCU

Author

Garcia M, Rivero M, Miranda-Bautista J, Baston-Rey I, Mesonero E, Leo-Carnerero E, Casas-Deza D, Fernandez C, Martin-Cardona A, El Hajra I, Hernandez-Aretxabaleta N, Perez-Martinez I, Fuentes-Valenzuela E, Jimenez N, de Celix C, Gutierrez A, Ferrer C, Huguer J, Fernandez-Cloter A, Gonzalez-Vivo M, Del Val B, Castro-Poceiro J, Melcarne L, Duenas C, Izquierdo M, Monfort D, Bouhmidi A, De la Piscina P, Romero E, Molina G, Zorrilla J, Calvino-Suarez C, Sanchez E, Nunez A, Sierra O, Castro B, Zabana Y, Gonzalez-Partida I, Chaparro M, and Gisbert J

Published
2021

21. P338 effectiveness and safety of biological therapies in elderly inflammatory bowel diseases patients results from a multi center study of Geteccu

Author

Suarez Ferrer, C J, primary, Mesonero, F, additional, Caballol, B, additional, Saiz Chumillas, R, additional, Bastón-Rey, I, additional, Rubin de Celix, C, additional, Melcarne, L, additional, Caballero Mateos, A, additional, Calafat, M, additional, Alonso Galan, H, additional, Vega Villaamil, P, additional, Castro Senosiain, B, additional, Rodriguez Diaz, C Y, additional, Plaza Santos, R, additional, Marques Cami, M, additional, Rodriguez Grau, M C, additional, Ramirez, F, additional, Lopez-García, A, additional, Gomez Pastrana, B, additional, Gonzalez Partida, I, additional, Botella Mateu, B, additional, Cuevas del Campo, L, additional, Gonzalez Peña, E, additional, Iyo, E, additional, Elosua Gonzalez, A, additional, Sainz, E, additional, Hernandez, L, additional, Perez Galindo, P, additional, Rueda Garcia, J L, additional, Martin-Arranz, M D, additional, Lopez Sanroman, A, additional, Fernandez-Clotet, A, additional, Sicilia, B, additional, Calviño Suárez, C, additional, Mañosa Ciria, M, additional, and Barreiro-De Acosta, M, additional

Published
2021
Full Text
View/download PDF

23. DOP40 Comorbidities and epidemiological risk factor but not immunosuppressive therapies increase the risk of COVID-19 in Inflammatory Bowel Disease (IBD): An ENEIDA-based, case-control study

Author

Zabana Abdo, Y, primary, Marín-Jiménez, I, additional, Rodríguez-Lago, I, additional, Vera, I, additional, Martín, M D, additional, Guerra, I, additional, Gisbert, J P, additional, Mesonero, F, additional, Benítez, O, additional, Taxonera, C, additional, Ponferrada-Díaz, Á, additional, Piqueras, M, additional, Lucendo, A, additional, Caballol, B, additional, Mañosa, M, additional, Martínez-Montiel, P, additional, Bosca-Watts, M, additional, Gordillo, J, additional, Bujanda, L, additional, Manceñido, N, additional, Martínez-Pérez, T, additional, López, A, additional, Rodríguez, C, additional, García-López, S, additional, Vega, P, additional, Rivero, M, additional, Melcarne, L, additional, Calvo, M, additional, Iborra, M, additional, Barreiro-de Acosta, M, additional, Arias, L, additional, Barrio, J, additional, Pérez, J L, additional, Busquets, D, additional, Pérez-Martínez, I, additional, Navarro-Llavat, M, additional, Hernández, V, additional, Argüelles-Arias, F, additional, Domènech, E, additional, and Esteve, M, additional

Published
2021
Full Text
View/download PDF

25. P319 Impact of biological agents on postoperative complications in inflammatory bowel disease: a multicentre study of GETECCU

Author

García García, M J, primary, Rivero, M, additional, Miranda-Bautista, J, additional, Bastón-Rey, I, additional, Mesonero, F, additional, Leo-Carnerero, E, additional, Casas-Deza, D, additional, Cagigas Fernández, C, additional, Martin-Cardona, A, additional, El Hajra, I, additional, Hernández-Aretxabaleta, N, additional, Pérez-Martínez, I, additional, Fuentes-Valenzuela, E, additional, Jiménez, N, additional, Rubín de Célix, C, additional, Gutiérrez, A, additional, Suárez Ferrer, C, additional, Huguet, J M, additional, Fernández-Clotet, A, additional, González-Vivó, M, additional, Del Val, B, additional, Castro-Poceiro, J, additional, Melcarne, L, additional, Dueñas, C, additional, Izquierdo, M, additional, Monfort, D, additional, Bouhmidi, A, additional, Ramírez De la Piscina, P, additional, Romero, E, additional, Molina, G, additional, Zorrilla, J, additional, Calvino-Suárez, C, additional, Sánchez, E, additional, Nuñez, A, additional, Sierra, O, additional, Castro, B, additional, Zabana, Y, additional, González-Partida, I, additional, Chaparro, M, additional, and Gisbert, J P, additional

Published
2021
Full Text
View/download PDF

28. EFFECT OF WEEKEND HOSPITAL ADMISSION ON LOWER GASTROINTESTINAL BLEEDING OUTCOMES

Author

Machlab, S, additional, Garcia - Iglesias, P, additional, Martinez-Bauer, E, additional, Brunet, E, additional, Hernandez, L, additional, Marin, S, additional, Raurich, M, additional, Puig-Divi, V, additional, Melcarne, L, additional, Calvet, X, additional, Junquera, F, additional, Fernandez, RC, additional, Montero, MG, additional, Brullet, E, additional, and Lira, A, additional

Published
2020
Full Text
View/download PDF

29. P743 Time trends of Crohn’s disease in Catalonia from 2011 to 2017. Increasing use of biologics correlates with a reduced need for surgery. A population-based study in Catalonia

Author

Brunet, E, primary, Melcarne, L, additional, Vela, E, additional, Clèries, M, additional, Pontes, C, additional, García-Iglesias, P, additional, Gallach, M, additional, Hernández, L, additional, Soria, A, additional, Jordi, V, additional, Pedregal, P, additional, Grau, G, additional, Garcia-Sagué, B, additional, Frisancho, L E, additional, Villòria, A, additional, Vergara, M, additional, and Calvet, X, additional

Published
2020
Full Text
View/download PDF

30. MUCOSAL ENDOSCOPIC RESECTION OF LARGE LESIONS OF THE UPPER DIGESTIVE TRACT

Author

Brunet Mas, E, additional, Martínez Bauer, E, additional, Garcia Iglesias, P, additional, Hernández, L, additional, Da Costa, J, additional, Llibre, G, additional, Soria, A, additional, Vives, J, additional, Pedregal, P, additional, Grau, G, additional, Lira, A, additional, Machlab, ST, additional, Melcarne, L, additional, Puig Diví, V, additional, Brullet, E, additional, Campo, R, additional, and Junquera, F, additional

Published
2019
Full Text
View/download PDF

31. OAKLAND SCORE IS NOT BETTER THAN HAEMOGLOBIN FOR PREDICTING OUTCOMES IN LOWER GASTROINTESTINAL BLEEDING

Author

Lira, A, additional, Machlab, S, additional, García-Iglesias, P, additional, Martínez-Bauer, E, additional, Mármol, C, additional, Gallach, M, additional, Hernández, L, additional, Brunet, E, additional, Melcarne, L, additional, Da Costa, J, additional, Llibre, G, additional, Puig-Diví, V, additional, Junquera, F, additional, Campo, R, additional, Calvet, X, additional, and Brullet, E, additional

Published
2019
Full Text
View/download PDF

32. GLASGOW-BLACHFORD SCORE ACCURATELY PREDICTS THE NEED OF CLINICAL INTERVENTION IN ACUTE LOWER GASTROINTESTINAL BLEEDING. A DIAGNOSTIC ACCURACY EVALUATION STUDY

Author

Lira, A, additional, Machlab, S, additional, Garcia-Iglesias, P, additional, Martinez-Bauer, E, additional, Mármol, C, additional, Llibre, G, additional, Da Costa, J, additional, Gallach, M, additional, Melcarne, L, additional, Puig-Diví, V, additional, Junquera, F, additional, Campo, R, additional, Calvet, X, additional, and Brullet, E, additional

Published
2019
Full Text
View/download PDF

33. Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

Author

Chaparro, María, primary, Donday, María G., additional, Barreiro-de Acosta, Manuel, additional, Domènech, Eugeni, additional, Esteve, María, additional, García-Sánchez, Valle, additional, Nos, Pilar, additional, Panés, Julián, additional, Martínez, Concepción, additional, Gisbert, Javier P., additional, Abad, F., additional, Aguas Peris, M., additional, Agüero Tejado, E., additional, Alba, C., additional, Albert, M., additional, Alemán, H., additional, Algaba, A., additional, Alonso Abreu, I., additional, Amador, M.P., additional, Amat, M., additional, Angueira, T., additional, Arajol, C., additional, Arias-González, L., additional, Arrondo Velasco, A., additional, Baldán, M., additional, Bardán García, B., additional, Bargalló García, A., additional, Barreiro de Acosta, M., additional, Barrio Andrés, J., additional, Bastida Paz, G., additional, Bastón Rey, I., additional, Batista, L., additional, Bellver Martínez, M., additional, Beltrán Niclós, B., additional, Benítez, J.M., additional, Ber Nieto, Y., additional, Bermejo, F., additional, Bernardo, D., additional, Blázquez Gómez, I., additional, Bouhmidi Assakali, A., additional, Busquets Casals, D., additional, Cabriada Nuño, J.L., additional, Calvet Calvo, X., additional, Calvo Hernández, M.V., additional, Calvo, M., additional, Camps, B., additional, Carbajo, A.Y., additional, Cardona Peitx, G., additional, Caro-Patón, T., additional, Carrillo Palau, M., additional, Carrión Bolorino, S., additional, Casanova, M.J., additional, Casellas Valdé, J.A., additional, Castaño García, A., additional, Castro Senosiain, B., additional, Ceballos, D., additional, Cerrillo, E., additional, Chacón Martínez, S., additional, Consuelo Cañete Pizarro, F., additional, de Castro Parga, M.L., additional, de Miguel, M., additional, de Francisco García, R., additional, de la Cruz Ramírez, M.D., additional, del Hoyo Francisco, J., additional, Delgado Guillena, P., additional, Desongles Corrales, T., additional, Echarri Piudo, A., additional, Espino Paisan, E., additional, Espona Quer, M., additional, Fernández Pordomingo, A., additional, Fernández Forcelledo, J.L., additional, Fernández-Tomé, S., additional, Ferreiro Iglesias, R., additional, Ferrer Bradley, I., additional, Ferrer, A., additional, Figueroa, A., additional, Gallach Montero, M., additional, García Iglesias, P., additional, García García-Lezcún, C., additional, García Ramírez, L., additional, García García, M.J., additional, García-Bosh, O., additional, Garre, A., additional, Giménez Poderós, T., additional, Gómez Irwin, L., additional, Gómez Pastrana, B., additional, Gómez Delgado, E., additional, González Lama, Y., additional, Gracia García, Á., additional, Gracia García, B., additional, Guardiola, J., additional, Guerra, I., additional, Guerra, E., additional, Guillot, V., additional, Gustmancher Saiz, S., additional, Gutiérrez Casbas, A., additional, Hernández Ramírez, V., additional, Hernando Verdugo, M.M., additional, Hernández Muniesa, B., additional, Hernanz Chaves, R., additional, Herrera Justiniano, J.M., additional, Hinojosa del Val, J, additional, Ibáñez Feijoo, S, additional, Iborra Colomino, M, additional, Iglesias Flores, E, additional, Izquierdo García, E., additional, Sampedro González, M J, additional, Lucendo, A J., additional, Jiménez García, N, additional, Leo Carnerero, E., additional, Loizaga Díaz, I., additional, López de Torre Querejazu, A, additional, López Sánchez, P, additional, Luis Parras, J, additional, Maia Boscá, M, additional, Mañosa, M, additional, Marín Pedrosa, S, additional, Marín, A, additional, Marinero, Á, additional, Marín-Jiménez, I, additional, Márquez Mosquera, L, additional, Márquez Galán, JL, additional, Martín Arranz, E, additional, Martín Arranz, MD, additional, Martínez Cadilla, J, additional, Martínez Sesmero, JM, additional, Martínez Sánchez, B, additional, Matallana, V, additional, Mateos Hernández, MI, additional, McNicholl, AG, additional, Mejuto Fernández, R, additional, Melcarne, L, additional, Menchén, L, additional, Méndez-Castrillón Rodríguez, J, additional, Merino Ochoa, O, additional, Mínguez, M, additional, Molas Ferrer, G, additional, Montoro Huguet, M, additional, Montserrat Torres, A, additional, Mora, F, additional, Moraleja Yudego, I, additional, Morales Alvarado, VJ, additional, Morales Martínez, L, additional, Morell, A, additional, Motos García, C, additional, Muñoz Alonso, F, additional, Muñoz Villafranca, MC, additional, Muñoz, JE, additional, Mur, A, additional, Nantes, Ó, additional, Navarro, P, additional, Navarro- Llavat, M, additional, Nos Mateu, P, additional, Núñez Alonso, A, additional, Núñez Ortiz, A, additional, Olivares, D, additional, Ollero Pena, V, additional, Orobitg, J, additional, Ortega, L, additional, Ortiz de Zárate, J, additional, Pallarés Manrique, H, additional, Paradela Carreiro, A, additional, Peral Ballester, L, additional, Pereira Bueno, S, additional, Pérez Martínez, I, additional, Pineda Mariño, JR, additional, Piñero Pérez, C, additional, Planas Giner, A, additional, Plaza Santos, MR, additional, Ponferrada Díaz, Á, additional, Poza Cardón, J, additional, Prieto Vicente, V, additional, Puchades, L, additional, Ramos López, L, additional, Redondo, S, additional, Riestra Menéndez, S, additional, Rivero Tirado, M, additional, Rodríguez Lago, I, additional, Rodríguez Gutiérrez, C, additional, Rodríguez, E, additional, Romero Izquierdo, S, additional, Rubio Iturria, S, additional, Ruiz Antorán, MB, additional, Ruiz, A, additional, Salazar, LF, additional, Sánchez Ulayar, A, additional, Sánchez Gómez, E, additional, Sánchez, C, additional, Sangrador, C, additional, Serra, K, additional, Spicakova, K, additional, Suárez Ferrer, C, additional, Talavera Fabuel, A, additional, Taxonera, C, additional, Tordera, M, additional, Torrella Cortés, E, additional, Tosca, J, additional, Trigo Salado, C, additional, Uriarte Estefanía, F, additional, Van Domselaar, M, additional, Vázquez Morón, JM, additional, Ventura López, P, additional, Vera, M, additional, Vicuña Arregui, M, additional, Villoria Ferrer, A, additional, Virgós Aller, T, additional, and Yáñez Feria, D, additional

Published
2019
Full Text
View/download PDF

34. The incidence of ulcer bleeding post endoscopic band ligation of esophageal varices

Author

Machlab, S., primary, Da Costa, J., additional, Horta, D., additional, Ruiz, P., additional, Profitós, J., additional, Gómez, M.V., additional, Miquel, M., additional, Casas, M., additional, Dalmau, B., additional, Campo, R., additional, Brullet, E., additional, Junquera, F., additional, Puig-Diví, V., additional, Martínez-Bauer, E., additional, García-Iglesias, P., additional, Villoria, A., additional, Gallach, M., additional, Melcarne, L., additional, Calvet, X., additional, and Sánchez-Delgado, J., additional

Published
2018
Full Text
View/download PDF

35. Effectiveness and safety of ustekinumab in bio-naïve Crohn’s disease patients: a multicentre observational retrospective study

Author

Valdés Delgado Teresa, Olmedo Martín Rául, Iborra Marisa, Herrera de Guisé Claudia, Fuentes-Valenzuela Esteban, Melcarne Luigi, Martín-Rodríguez Mª Mar, Kolle Casso Lilyan, De Castro Parga Luisa, Ponferrada Díaz Ángel, Vicente Lidón Raquel, Manceñido Marcos Noemí, Velayos Jiménez Benito, Lázaro Sáez Marta, López Cauce Beatriz, Mesonero Gismero Francisco, Gilabert Álvarez Pau, and Argüelles-Arias Federico

Subjects
Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Background: Clinical trials have demonstrated the efficacy and safety of ustekinumab in Crohn’s disease (CD). However, more data are necessary on the effectiveness of ustekinumab in bio-naïve patients in real-life studies. Objectives: The aim of our study was to evaluate the effectiveness and safety of ustekinumab in patients with CD refractory or intolerant to conventional therapy and without previous exposure to biological drugs. Design: We performed a nationwide, observational, retrospective, multicentre study including patients with CD, in which ustekinumab was used as the first biological drug. Methods: The corticosteroid-free clinical and biological response and remission were analysed at weeks 16, 24, 52 and 72. Clinical remission was defined as Harvey–Bradshaw index ⩽ 4 and biological remission as a faecal calprotectin (FC)

Published
2023
Full Text
View/download PDF

47. Effectiveness of biological treatments for inflammatory bowel disease in the elderly patients

Author

Suarez Ferrer, C. J., Mesonero, F., Caballol, B., Maria Pilar Ballester, Baston Rey, I., Castano Garcia, A., Miranda Bautista, J., Saiz Chumillas, R., Benitez, J. M., Sanchez Delgado, L., Lopez-Garcia, A., Rubin Celix, C., Martin-Arranz, M. D., Lopez Sanroman, A., Fernandez-Clotet, A., Merino Murgui, V., Calvino Suarez, C., Florez, P., Lobato Matilla, M. E., Sicilia, B., Soto Escribano, P., Maroto Martin, C., Alonso Abreu, I., Melcarne, L., Elena, P. G., Iyo, E., Elosua Gonzalez, A., Saiz, E., Hernandez Villalba, L., Perez Galindo, P., Torrealba Medina, L., Monsalve Alonso, S., Olmos Jerez, J. A., Duenas Sadornil, C., and Barreiro-De Acosta, M.

48. Profile of elderly patients in which biological drugs are used for the treatment of inflammatory bowel disease

Author

Suarez Ferrer, C. J., Mesonero, F., Caballol, B., Maria Pilar Ballester, Baston Rey, I., Castano Garcia, A., Miranda Bautista, J., Saiz Chumillas, R., Benitez, J. M., Sanchez Delgado, L., Lopez-Garcia, A., Rubin Celio, C., Alonso Abreu, I., Melcarne, L., Plaza Santos, R., Marques Cami, M., Caballero Mateos, A., Gomez Diez, C., Calafat, M., Alonso Galan, H., Vega Vilaamil, P., Castro Sensosian, B., Guerro Moya, A., Rodriguez Diaz, C. Y., Spicakova, K., Mancenido Marcos, N., Molina, G., Castro, L., Rodriguez Angulo, A., Cuevas Del Campo, L., Rodriguez Grau, M. C., Ramirez, F., Gomez Pastrana, B., Gonzalez Partida, I., Botella Mateu, B., Pena Gonzalez, E., Iyo, E., Elosua Gonzalez, A., Manosa Ciria, M., and Barreiro-De Acosta, M.

49. Efficacy and safety of biological treatment for inflammatory bowel disease in elderly patients: Results from a GETECCU cohort.

Author

Suárez Ferrer C, Mesonero Gismero F, Caballol B, Ballester MP, Bastón Rey I, Castaño García A, Miranda Bautista J, Saiz Chumillas R, Benitez JM, Sanchez-Delgado L, López-García A, Rubin de Celix C, Alonso Abreu I, Melcarne L, Plaza Santos R, Marques-Camí M, Caballero Mateos A, Gómez Díez C, Calafat M, Galan HA, Vega Vilaamil P, Castro Senosiain B, Guerro Moya A, Rodriguez Diaz CY, Spicakova K, Manceñido Marcos N, Molina G, de Castro Parga L, Rodriguez Angulo A, Cuevas Del Campo L, Rodriguez Grau MDC, Ramirez F, Gomez Pastrana B, Gonzalez Partida I, Botella Mateu B, Peña Gonzalez E, Iyo E, Elosua Gonzalez A, Sainz Arnau E, Hernandez Villalba L, Perez Galindo P, Torrealba Medina L, Monsalve Alonso S, Olmos Perez JA, Dueñas Sadornil C, Garcia Ramirez L, Martín-Arranz MD, López Sanroman A, Fernández A, Merino Murgui V, Calviño Suárez C, Flórez-Diez P, Lobato Matilla ME, Sicilia B, Soto Escribano P, Maroto Martin C, Mañosa M, and Barreiro-De Acosta M

Subjects
Humans, Aged, Male, Female, Retrospective Studies, Treatment Outcome, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal adverse effects, Aged, 80 and over, Adalimumab therapeutic use, Adalimumab adverse effects, Ustekinumab therapeutic use, Ustekinumab adverse effects, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized adverse effects, Biological Therapy adverse effects, Remission Induction, Inflammatory Bowel Diseases drug therapy
Abstract

Introduction: Biological therapies used for the treatment of inflammatory bowel disease (IBD) have shown to be effective and safe, although these results were obtained from studies involving mostly a young population, who are generally included in clinical trials. The aim of our study was to determine the efficacy and safety of the different biological treatments in the elderly population., Methods: Multicenter study was carried out in the GETECCU group. Patients diagnosed with IBD and aged over 65 years at the time of initiating biological therapy (infliximab, adalimumab, golimumab, ustekinumab or vedolizumab) were retrospectively included. Among the patients included, clinical response was assessed after drug induction (12 weeks of treatment) and at 52 weeks. Patients' colonoscopy data in week 52 were assessment, where available. Regarding complications, development of oncological events during follow-up and infectious processes occurring during biological treatment were collected (excluding bowel infection by cytomegalovirus)., Results: A total of 1090 patients were included. After induction, at approximately 12-14 weeks of treatment, 419 patients (39.6%) were in clinical remission, 502 patients (47.4%) had responded without remission and 137 patients (12.9%) had no response. At 52 weeks of treatment 442 patients (57.1%) had achieved clinical remission, 249 patients had responded without remission (32.2%) and 53 patients had no response to the treatment (6.8%). Before 52 weeks, 129 patients (14.8%) had discontinued treatment due to inefficacy, this being significantly higher (p<0.0001) for Golimumab - 9 patients (37.5%) - compared to the other biological treatments analyzed. With respect to tumor development, an oncological event was observed in 74 patients (6.9%): 30 patients (8%) on infliximab, 23 (7.14%) on adalimumab, 3 (11.1%) on golimumab, 10 (6.4%) on ustekinumab, and 8 (3.8%) on vedolizumab. The incidence was significantly lower (p=0.04) for the vedolizumab group compared to other treatments. As regards infections, these occurred in 160 patients during treatment (14.9%), with no differences between the different biologicals used (p=0.61): 61 patients (19.4%) on infliximab, 39 (12.5%) on adalimumab, 5 (17.8%) on golimumab, 22 (14.1%) on ustekinumab, and 34 (16.5%) on vedolizumab., Conclusions: Biological drug therapies have response rates in elderly patients similar to those described in the general population, Golimumab was the drug that was discontinued most frequently due to inefficacy. In our experience, tumor development was more frequent in patients who used anti-TNF therapies compared to other targets, although its incidence was generally low and that this is in line with younger patients based on previous literature., (Copyright © 2024 Elsevier España, S.L.U. All rights reserved.)

Published
2024
Full Text
View/download PDF

50. Telemonitoring of Active Inflammatory Bowel Disease Using the App TECCU: Short-Term Results of a Multicenter Trial of GETECCU.

Author

Aguas M, Del Hoyo J, Vicente R, Barreiro-de Acosta M, Melcarne L, Hernandez-Camba A, Madero L, Arroyo MT, Sicilia B, Chaparro M, Martin-Arranz MD, Pajares R, Mesonero F, Mañosa M, Martinez P, Chacón S, Tosca J, Marín S, Sanroman L, Calvo M, Monfort D, Saiz E, Zabana Y, Guerra I, Varela P, Baydal V, Faubel R, Corsino P, Porto-Silva S, Brunet E, González M, Gutiérrez A, and Nos P

Subjects
Humans, Female, Male, Adult, Middle Aged, Mobile Applications, Spain, Crohn Disease drug therapy, Telemedicine, Inflammatory Bowel Diseases drug therapy, Inflammatory Bowel Diseases therapy, Quality of Life
Abstract

Background: Telemonitoring for inflammatory bowel disease (IBD) has not consistently demonstrated superiority over standard care; however, noninferiority may be an acceptable outcome if remote care proves to be more efficient., Objective: This study aims to compare the remission time and quality of life of patients with active IBD managed through standard care versus the TECCU (Telemonitoring of Crohn Disease and Ulcerative Colitis) app., Methods: A 2-arm, randomized, multicenter trial with a noninferiority design was conducted across 24 hospitals in Spain. The study included adult patients with IBD who were starting immunosuppressive or biological therapy. Participants were randomized into 2 groups: the telemonitoring group (G&#95;TECCU) and the standard care group (G&#95;Control). The follow-up schedule for the telemonitoring group (G&#95;TECCU) was based on contacts via the TECCU app, while the control group (G&#95;Control) adhered to standard clinical practice, which included in-person visits and telephone calls. In both groups, treatment adjustments were made based on the progression of disease activity and medication adherence, assessed using specific indices and biological markers at each check-up. The primary outcome was the duration of remission after 12 weeks, while secondary outcomes included quality of life, medication adherence, adverse events, and patient satisfaction., Results: Of the 169 patients enrolled, 158 were randomized and 150 were analyzed per protocol: telemonitoring (n=71) and control (n=79). After 12 weeks, the time in clinical remission was not inferior in the telemonitoring group (mean 4.20, SD 3.73 weeks) compared with the control group (mean 4.32, SD 3.28 weeks), with a mean difference between arms of -0.12 weeks (95% CI -1.25 to 1.01; noninferiority P=.02). The mean reduction in C-reactive protein values was -15.40 mg/L (SD 90.15 mg/L; P=.19) in the G&#95;TECCU group and -13.16 mg/L (SD 54.61 mg/L; P=.05) in the G&#95;Control group, with no significant differences between the 2 arms (P=.73). Similarly, the mean improvement in fecal calprotectin levels was 832.3 mg/L (SD 1825.0 mg/L; P=.003) in the G&#95;TECCU group and 1073.5 mg/L (SD 3105.7 mg/L; P=.03) in the G&#95;Control group; however, the differences were not statistically significant (P=.96). Quality of life improved in both groups, with a mean increase in the 9-item Inflammatory Bowel Disease Questionnaire score of 13.44 points (SD 19.1 points; P<.001) in the G&#95;TECCU group and 18.23 points (SD 22.9 points; P=.001) in the G&#95;Control group. Additionally, the proportion of patients who adhered to their medication significantly increased from 35% (25/71) to 68% (48/71) in the G&#95;TECCU group (P=.001) and from 46% (36/79) to 73% (58/79) in the G&#95;Control group (P=.001). The satisfaction rate remained stable at around 90%, although noninferiority was not demonstrated for the secondary outcomes., Conclusions: Telemonitoring patients with active IBD is not inferior to standard care for achieving and maintaining short-term remission. The TECCU app may serve as a viable alternative follow-up tool, pending confirmation of improved health outcomes and cost-effectiveness over the long-term., Trial Registration: ClinicalTrials.gov NCT06031038; https://clinicaltrials.gov/ct2/show/NCT06031038., International Registered Report Identifier (irrid): RR2-10.2196/resprot.9639., (©Mariam Aguas, Javier Del Hoyo, Raquel Vicente, Manuel Barreiro-de Acosta, Luigi Melcarne, Alejandro Hernandez-Camba, Lucía Madero, María Teresa Arroyo, Beatriz Sicilia, María Chaparro, María Dolores Martin-Arranz, Ramón Pajares, Francisco Mesonero, Miriam Mañosa, Pilar Martinez, Silvia Chacón, Joan Tosca, Sandra Marín, Luciano Sanroman, Marta Calvo, David Monfort, Empar Saiz, Yamile Zabana, Ivan Guerra, Pilar Varela, Virginia Baydal, Raquel Faubel, Pilar Corsino, Sol Porto-Silva, Eduard Brunet, Melodi González, Ana Gutiérrez, Pilar Nos. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 18.11.2024.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results